Previous studies identified focal adhesion kinase (FAK) signaling as a central regulator of YAP activity in other cancer cell contexts, offering a non-canonical alternative mechanism for YAP activation and potential clinical intervention using emerging FAK inhibitors29. This evidence concerns the gene PTK2 and cancer.